がん生物学的療法の市場：療法タイプ、がんタイプ、エンドユーザー、地域別、2026～2032年

がん生物学的療法市場の評価-2026-2032

世界のがん罹患率の増加が、革新的な治療オプションへの需要を押し上げ、がん生物学的療法の採用を促進しています。個人の遺伝子プロファイルに合わせた治療に焦点を当てた個別化医療へのシフトは、市場規模を2024年に937億4,000万米ドルを突破し、2032年には約1,533億5,000万米ドルの評価額に達する原動力となっています。

これに加えて、生物学的療法による臨床的成功や患者の転帰の改善が、がん生物学的療法の採用に拍車をかけています。がん研究・治療に対する政府資金の増加と有利な政策により、市場は2026年から2032年にかけてCAGR 7%で成長します。

がん生物学的療法市場定義/概要

がん生物学的療法は、生物学的療法または免疫療法としても知られ、がんを治療するために生体、生体由来の物質、またはそのような物質の合成版を使用します。これらの治療法は、がんと闘うための身体の自然な防御機能を強化したり、がんの増殖や進行に関与する特定の分子を標的とすることで機能します。生物学的療法の例としては、モノクローナル抗体、がんワクチン、細胞ベース療法などがあります。

がん生物学的療法は、様々な種類のがんの治療に使用され、多くの場合、化学療法、放射線療法、手術などの他の治療と併用されます。これらは、正常細胞へのダメージを最小限に抑えながら、特定のがん細胞を標的にするのに特に効果的です。モノクローナル抗体は、がん細胞の増殖を阻害したり、免疫系による破壊のためにがん細胞に目印をつけたり、放射線や化学療法を直接がん細胞に届けたりするために使用されます。がんワクチンは、がん細胞を攻撃するよう免疫系を刺激することを目的とし、CAR T細胞療法などの細胞ベース療法は、がんをより効果的に攻撃するよう患者自身の免疫細胞を改変します。

世界のがん罹患率の増加は、どのようにがん生物学的療法の採用を増加させるのか？

世界のがん罹患率の上昇は、がん生物学的療法市場の主な促進要因です。世界保健機関（WHO）によると、がん患者は2020年のレベルから2040年までに60％増加すると予測されています。米国国立がん研究所によれば、約39.5％の人が一生のうちに一度はがんと診断されるといいます。このような負担の増加により、生物学的療法のような効果的で的を絞った治療に対する需要が高まっています。この動向を受けて、メルク社は2024年2月、新規チェックポイント阻害剤を中心とした免疫腫瘍学パイプラインの拡充を発表しました。同様に、ロシュは2024年4月、mRNA技術と確立された生物学的療法を組み合わせた新しい個別化がんワクチン・プラットフォームを発表しました。

バイオテクノロジーの進歩とがん生物学に対するより深い理解が、生物学的療法の技術革新に拍車をかけています。米国食品医薬品局（FDA）は、2020年から2024年の間に、がん治療のための18の新しい生物学的療法を承認しました。欧州医薬品庁（European Medicines Agency）の報告書によると、2021年から2023年にかけて、がんを対象とした生物学的療法の臨床試験は35%増加します。これらの開発により、副作用の少ない、より効果的で的を絞った治療が実現しつつあります。2024年3月、ブリストル・マイヤーズスクイブ社が固形がんに対する画期的なCAR-T細胞療法を発表し、この生物学的アプローチの適用が拡大しました。ノバルティスは2024年5月、多発性骨髄腫をターゲットとする二重特異性抗体の第Ⅲ相臨床試験結果が成功し、無増悪生存期間が大幅に改善したことを発表しました。

がん生物学的療法へのアクセスや利用可能性の欠如は、その適用を抑制するか？

がん生物学的療法市場における重大な抑制要因の1つは、これらの治療に関連する高コストです。モノクローナル抗体やCAR T細胞療法などの生物学的療法は、開発、製造、投与にコストがかかることが多いです。このコストには、複雑な製造工程だけでなく、訓練を受けたヘルスケア専門家による専門的な取り扱いや投与の必要性も含まれます。このような経済的負担は、特に低・中所得国において、多くの患者のアクセスを制限する可能性があり、ヘルスケアシステムや保険プロバイダーにとって、これらの先進的治療に伴う高額な費用を管理する上での課題となっています。

がん生物学的療法へのアクセスや利用可能性の欠如も大きな課題です。これらの治療は特殊であるため、すべての地域、特に遠隔地や低開発地域では広く利用できない可能性があります。専門施設や訓練を受けた人材など、高度なヘルスケア・インフラが必要なため、生物学的療法の普及はさらに制限されます。さらに、規制当局の承認や市場参入の障壁により、新しい治療法の利用が遅れ、これらの治療法を必要としている患者へのタイムリーな提供に影響を及ぼす可能性があります。

がん生物学的療法は、サイトカイン放出症候群（CRS）のような重大な副作用や予期せぬ免疫反応を引き起こす可能性があります。これらの副作用は慎重なモニタリングを必要とし、治療プロトコルを複雑にするため、臨床医にとっては有効性と安全性のバランスをとることが課題となります。重篤な副作用は患者を不安にさせ、生物学的治療を管理する医療従事者にさらなる課題をもたらします。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 がん生物学的療法市場：療法タイプ別

• モノクローナル抗体
• がんワクチン
• サイトカイン
• 遺伝子療法
• 標的療法
• その他

第5章 がん生物学的療法市場：がんタイプ別

• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• 白血病
• リンパ腫
• その他

第6章 がん生物学的療法市場：エンドユーザー別

• 病院
• がん治療センター
• 診療所
• 外来手術センター
• その他

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Amgen
• F. Hoffmann-La Roche
• Merck Group
• Eli Lilly and Company
• GSK（GlaxoSmithKline）
• Bristol Myers Squibb
• Novartis
• Celgene（acquired by Bristol Myers Squibb）
• Spectrum Pharmaceuticals
• AbbVie
• AstraZeneca
• Astellas
• International

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Cancer Biological Therapy Market Valuation - 2026-2032

Increasing global prevalence of cancer boosts demand for innovative treatment options is propelling the adoption of cancer biological therapy. The shift towards personalized medicine, focusing on treatments tailored to individual genetic profiles is driving the market size surpass USD 93.74 Billion valued in 2024 to reach a valuation of around USD 153.35 Billion by 2032.

In addition to this, clinical success and improved patient outcomes with biological therapies are spurring up the adoption of cancer biological therapy. Increased government funding and favorable policies for cancer research and treatment is enabling the market to grow at a CAGR of 7% from 2026 to 2032.

Cancer Biological Therapy Market: Definition/ Overview

Cancer biological therapy, also known as biotherapy or immunotherapy, involves the use of living organisms, substances derived from living organisms, or synthetic versions of such substances to treat cancer. These therapies work by enhancing the body's natural defenses to fight cancer or by targeting specific molecules involved in cancer growth and progression. Examples of biological therapies include monoclonal antibodies, cancer vaccines, and cell-based therapies.

Cancer biological therapies are used to treat various types of cancer, often in combination with other treatments such as chemotherapy, radiation, and surgery. They are particularly effective in targeting specific cancer cells while minimizing damage to normal cells. Monoclonal antibodies can be used to block cancer cell growth, mark cancer cells for destruction by the immune system, or deliver radiation or chemotherapy directly to cancer cells. Cancer vaccines aim to stimulate the immune system to attack cancer cells, and cell-based therapies, such as CAR T-cell therapy, involve modifying a patient's own immune cells to target cancer more effectively.

How will Rising Global Cancer Prevalence Increase Adoption of Cancer Biological Therapy?

The rising global cancer prevalence is a primary driver of the cancer biological therapy market. According to the World Health Organization, cancer cases are projected to increase by 60% by 2040 from 2020 levels. The U.S. National Cancer Institute reported that approximately 39.5% of people will be diagnosed with cancer at some point in their lives. This increasing burden has led to greater demand for effective and targeted treatments like biological therapies. In response to this trend, Merck announced in February 2024 the expansion of its immuno-oncology pipeline, focusing on novel checkpoint inhibitors. Similarly, Roche introduced a new personalized cancer vaccine platform in April 2024, combining mRNA technology with their established biological therapies.

Advancements in biotechnology and a deeper understanding of cancer biology are fueling innovation in biological therapies. The U.S. Food and Drug Administration (FDA) approved 18 new biological therapies for cancer treatment between 2020 and 2024. A report from the European Medicines Agency showed a 35% increase in biological therapy clinical trials for cancer from 2021 to 2023. These developments are leading to more effective and targeted treatments with fewer side effects. In March 2024, Bristol Myers Squibb unveiled a groundbreaking CAR-T cell therapy for solid tumors, expanding the application of this biological approach. Novartis announced in May 2024 the successful phase III trial results for a bispecific antibody targeting multiple myeloma, demonstrating significant improvements in progression-free survival.

Will Lack of Accessibility and Availability of Cancer Biological Therapy Restrain Its Application?

One of the significant restraints in the cancer biological therapy market is the high cost associated with these treatments. Biological therapies, such as monoclonal antibodies and CAR T-cell therapy, are often expensive to develop, produce, and administer. The costs include not only the complex manufacturing processes but also the need for specialized handling and administration by trained healthcare professionals. This financial burden can limit accessibility for many patients, particularly in low- and middle-income countries, and poses a challenge for healthcare systems and insurance providers in managing the high expenses associated with these advanced treatments.

Lack of accessibility and availability of cancer biological therapies are also major challenges. Due to the specialized nature of these treatments, they may not be widely available in all regions, particularly in remote or underdeveloped areas. The need for sophisticated healthcare infrastructure, including specialized facilities and trained personnel, further restricts the widespread adoption of biological therapies. Additionally, regulatory approvals and market entry barriers can delay the availability of new treatments, impacting the timely delivery of these therapies to patients in need.

Cancer biological therapies can cause significant adverse effects and unintended immune responses, such as cytokine release syndrome (CRS). These side effects require careful monitoring and complicate treatment protocols, making it challenging for clinicians to balance efficacy and safety. Severe side effects can deter patients and create additional challenges for healthcare providers in managing biological treatments.

Category-Wise Acumens

Will Rise in Adoption of Monoclonal Antibodies (mAbs) Drive Cancer Biological Therapy Market?

Monoclonal antibodies (mAbs) is emerging as the leading segment in the cancer biological therapy market. According to the FDA, mAbs accounted for 35% of all cancer biological therapy approvals between 2020 and 2024. The National Cancer Institute reported that mAb therapies were used in 40% of cancer treatment regimens in the U.S. by 2023. This dominance is attributed to their high specificity and efficacy in targeting cancer cells. In February 2024, Roche announced the successful phase III trial results for a novel bispecific antibody targeting both HER2 and PD-1 in breast cancer patients. Similarly, Merck launched an advanced mAb therapy in April 2024, demonstrating improved overall survival rates in lung cancer patients.

The versatility of monoclonal antibodies in combination therapies is driving their market growth. The American Society of Clinical Oncology reported a 28% increase in clinical trials involving mAb combination therapies from 2021 to 2023. The European Medicines Agency approved 15 new mAb-based combination treatments between 2020 and 2024. This trend reflects the growing recognition of mAbs' potential to enhance treatment efficacy when used with other therapies. In March 2024, Bristol Myers Squibb introduced a groundbreaking triple combination therapy featuring two mAbs and a small molecule inhibitor for advanced melanoma. AstraZeneca partnered with a leading biotech firm in May 2024 to develop next-generation antibody-drug conjugates for multiple cancer types.

Which Factors Enhance the Use of Cancer Biological Therapy in Hospitals?

Hospitals is expected to emerge as the primary distribution channel for cancer biological therapies. According to the American Hospital Association, 72% of all cancer biological treatments were administered in hospital settings in 2023. The Centers for Medicare & Medicaid Services reported that hospital outpatient departments accounted for 65% of cancer biological therapy claims in 2024. This dominance is attributed to the complex nature of these treatments and the need for specialized care. In February 2024, the Mayo Clinic announced the expansion of its cancer biological therapy units across all major branches. Similarly, Cleveland Clinic partnered with Roche in April 2024 to establish advanced biological therapy infusion centers in its hospitals.

The rise of hospital-based cancer centers is fueling the growth of biological therapy administration. The National Cancer Institute reported a 30% increase in NCI-designated cancer centers from 2020 to 2024. A survey by the American Society of Clinical Oncology found that 80% of oncologists preferred hospital settings for administering complex biological therapies in 2023. This trend reflects the need for comprehensive care and immediate access to emergency services. In March 2024, MD Anderson Cancer Center unveiled a state-of-the-art biological therapy wing, featuring personalized treatment suites. NewYork-Presbyterian Hospital launched an integrated immunotherapy program in May 2024, centralizing all biological therapy services.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure in North America Mature Cancer Biological Therapy Market?

North America leads the global cancer biological therapy market due to advanced healthcare infrastructure and high adoption rates. According to the National Cancer Institute, biological therapies accounted for 35% of all cancer treatments in the U.S. by 2023. The Canadian Cancer Society reported a 28% increase in biological therapy usage from 2020 to 2024. This dominance is fueled by substantial research funding and a robust biotechnology industry. In February 2024, the U.S. FDA approved a record number of 12 new cancer biological therapies. Merck, a key player, announced in April 2024 a USD 2 Billion investment to expand its biological therapy production facilities across North America.

The region's strong reimbursement policies and insurance coverage drive market growth. The Centers for Medicare & Medicaid Services reported that spending on cancer biological therapies increased by 40% between 2020 and 2024. A study by the American Cancer Society found that 85% of cancer patients had access to biological therapies through insurance in 2023. This financial support enhances patient access to advanced treatments. In March 2024, UnitedHealth Group expanded its coverage for CAR-T cell therapies, benefiting thousands of cancer patients. Roche partnered with major U.S. insurers in May 2024 to introduce innovative payment models for its portfolio of biological cancer treatments.

North America's leadership in clinical trials and personalized medicine boosts its market position. The NIH Clinical Trials database showed that 60% of global cancer biological therapy trials were conducted in North America in 2023. Health Canada reported a 25% increase in precision medicine approvals for cancer from 2021 to 2024. This focus on innovation drives the development of more effective therapies. In January 2024, Gilead Sciences launched a groundbreaking personalized neoantigen therapy in the U.S. market. Bristol Myers Squibb announced in June 2024 the successful completion of the largest pan-cancer immunotherapy trial to date, conducted across multiple North American centers.

Will Increasing Cancer Prevalence Enhance Adoption of Cancer Biological Therapy in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the cancer biological therapy market due to increasing cancer prevalence and improving healthcare infrastructure. According to the World Health Organization, cancer cases in Asia are projected to increase by 35% from 2020 to 2030. China's National Cancer Center reported a 25% rise in biological therapy adoption from 2021 to 2023. This growth is driven by government initiatives and rising healthcare expenditure. In February 2024, the Indian Council of Medical Research announced a $500 million investment in cancer biological therapy research. Japan's Ministry of Health approved 8 new cancer biological therapies in 2023, marking a 40% increase from the previous year.

Expansion of local biopharmaceutical companies and partnerships with global players are fueling market growth. The China National Medical Products Administration reported a 30% increase in domestic cancer biological therapy approvals between 2020 and 2024. South Korea's Ministry of Food and Drug Safety noted a 45% growth in biological therapy clinical trials from 2022 to 2024. These developments are enhancing the region's capacity for advanced cancer treatments. In March 2024, BeiGene partnered with Novartis to expand its biological therapy portfolio across Asia. Singapore-based Tessa Therapeutics raised $200 million in April 2024 to advance its CAR-T cell therapy pipeline for solid tumors. At the forefront, the availability of local vendors offering competitive pricing cloud-based solutions increase the accessibility and availability of Cancer Biological Therapy to businesses of all sizes, driving wider adoption.

Competitive Landscape

The cancer biological therapy market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the cancer biological therapy market include:

• Bristol-Myers Squibb
• Merck & Co., Inc.
• Roche Holding AG
• Novartis International AG
• AstraZeneca
• Pfizer, Inc.
• Amgen, Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Sanofi S.A.
• Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
• Gilead Sciences, Inc.
• AbbVie, Inc.
• Biogen, Inc.
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals, Inc.
• Seagen, Inc.
• Incyte Corporation
• Adaptimmune Therapeutics plc.

Latest Developments

• In September 2023, Novartis received FDA approval for a next-generation targeted therapy for breast cancer, marking a significant advancement in precision medicine and biological treatments.
• In August 2023, AstraZeneca announced a collaboration with a leading research institute to explore the use of gene editing technologies in developing new biological therapies for lung cancer.

Cancer Biological Therapy Market, By Category

• Type of Therapy:
• Monoclonal Antibodies
• Cancer Vaccines
• Cytokines
• Gene Therapy
• Targeted Therapy
• Cancer Type:
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma
• End-User:
• Hospitals
• Cancer Treatment Centers
• Clinics
• Ambulatory Surgical Centers
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Cancer Biological Therapy Market, By Type of Therapy

• Monoclonal Antibodies
• Cancer Vaccines
• Cytokines
• Gene Therapy
• Targeted Therapy
• Others

5. Cancer Biological Therapy Market, By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma
• Others

6. Cancer Biological Therapy Market, By End User

• Hospitals
• Cancer Treatment Centers
• Clinics
• Ambulatory Surgical Centers
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Amgen
• F. Hoffmann-La Roche
• Merck Group
• Eli Lilly and Company
• GSK (GlaxoSmithKline)
• Bristol Myers Squibb
• Novartis
• Celgene (acquired by Bristol Myers Squibb)
• Spectrum Pharmaceuticals
• AbbVie
• AstraZeneca
• Astellas
• International

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References